Tellison, thanks for sharing a bit of your story puts all this into proper perspective. I too lost a wife to cancer but the good Lord put another great lady into my life I hope you are as blessed. My adult kids own shares as well; exciting times for the family... hugs

I live in tempe..small world

Vascepa lowered my insulin resistance a trial of one but I may not be abby normal :)

I suspect we get another cc post 11-10 unveiling

A reminder that the cardiometabolic Congress meeting is this week beginning on the 24th. As bio has suggested this will be newsworthy for us longs as Bhatt, Ballantyne, Bays,Blonde and Busch will be presenting. Amarin is all over this meeting as a Sponsor. Nice find bio bill

Could, I'm a 57 yr Male 190 lb 5'11. Haven't gone back to discuss with doc. Labs were good other than a1c

Could, I was prediabetic on metformin and was able to discontinue the metformin after about 60 days on 4g of vascepa. I tested my levels 2 to 3xs daily

Zip and others, I couldn't agree more the adcom was a sham and sick people died because of it. The safety profile made it easy for them to explore other options they chose not to

he missed a great opportunity to educate to his readership

Everybody has a Cramer story. Mine is exas at $8 has gone on to to 80. In fairness he did eventually have the CEO on but he never understood the market

key takeaway from JT today
I'm hoping that it doesn't lead them or physicians to believe that triglyceride lowering alone would be sufficient because this was not a triglyceride lowering study. This is a study of outcomes with a specific drug with a specific profile and that's what people should take out of it.

MNbio..I've been ranjo on exas board for years what's your name over there?..and I agree with your sentiments regarding amrn..thanks for chiming in

good find always... not that amrn needs green but helps our mood :)

well done HS! I take my 3k every year I think forever against future capital gains :)

bought more myself this morning

bfost, congrats on another winner!

75% is what I recall

new money I added on the swoon today .. will add on any weakness as I suspect the type 2 population will be swallowing 4 g's of vascepa a day that's 100's of millions globally... more to be revealed 11-10-18. Our challenge isn't new indications it is going to be supply as has been discussed ad nauseum on this board

mark, your conjecture is as likely as any I've read on here this week.. why not...market close tomorrow should be fun

I've been long this stock over 3k days what's another 12 :)

Bio, with Vascepa's safety profile I also would like to see a harms/benefits comparison

yup relatively good ah volume all above 2.9 not a bad thing

biobill, because of the safety profile of vascepa I think it poses a problem for the FDA to delay this any further with a statistically significant reduce it ; its a great 60 minute's episode

hit pieces are very very common and it won't be the last even with a successful reduce it people will dissect parts of reduce it to validate their short position. that's why it is important to know why and what you own

Mrmain- no never seen this especially with our float

HSpooner, yeah the relationship matters as I have educated more than one GI, PCP's, and physician assistants on various drugs/diagnostics. I have had them buy the stock after I got through discussing it with them and i'm just a silly ol' patient of record. 10.2 million FIT were ordered last year to screen for colorectal cancer when a much better non invasive mouse trap is available.. same out of pocket costs same hedis and stars rewards... why? the PCP's don't have the time to educate themselves or perhaps prescribing habits are hard to break?? but its called supervised neglect and it happens everyday in most practices. the paradigm is fish oil is fish oil and it works marginally if at all .. now with a successful reduce it someone needs to explain why 4 g's of highly purified EPA is therapeutic ? I can do it in 2 minutes but I have to be able to get in front of the prescriber for that to be meaningful.

JL completely agree its doc education opportunity. A rep has to be able to see the doc to educate him/her. Pfizer reps will be able to see a doc quicker than an amrn rep.i wish the most efficacious drugs were always prescibed.

be careful to assume the rest of the world is going to be aware of a successful reduce it … no way amrn markets this alone if at all.. remember docs are still prescribing fibrates

clearly no run up into top line revelation makes me think beyond its efficacy what else am I missing

I think we are looking at this scenario sooner than later no way amrn is going to put together a sales team to effectively market what I think the future has in store for Vascepa

In 1996 Warner-Lambert entered into a co-marketing agreement with Pfizer to sell Lipitor and in 2000 Pfizer acquired Warner-Lambert 2000 for $90.2 billion.[2][3][5][6] Lipitor was on the market by 1996.[7][58] By 2003 Lipitor had become the best selling pharmaceutical in the United States.[4] From 1996 to 2012 under the trade name Lipitor, atorvastatin became the world's best-selling medication of all time, with more than $125 billion in sales over approximately 14.5 years.[8] Lipitor alone "provided up to a quarter of Pfizer Inc.'s annual revenue for years."[8]
Pfizer's patent on atorvastatin expired in November 2011.[59]

onegragman, I'm with you on a big DTC spend before any of our thoughts work we have to have the insurance in place. Doc's will hesitate if they are unsure of out of pocket costs. I was told Tier 2 is where we need to be quickly.

Oneragman, big pharma reps in CV space are going to exponentially create more awareness. Especially if we can be #2 in their bag. 100k's more calls per year in addition to amrn reps. If reduce it shows what I think it will, we need to be calling on every primary;every cardiologist and every endocrinologist. There are 200k+ PCP's alone. The ramp on Vascepa will be a hockey stick shape time is money.

Find it hard to believe they won't co promote with big pharma in CV space. They need results before they implement a co promote but it has to be negotiated as we discuss reduce it outcome.

yes stc they will liquidate .. I've had luck in the past by talking to them and putting a game plan together

I called my margin folk at TD and they relaxed the requirement a month or so ago .. I hate having to sell before I even get to the finish line! I know its about risk management but I always thought it was a way of stealing shares

I called my margin folk at TD and they relaxed the requirement a month or so ago .. I hate having to sell before I even get to the finish line! I know its about risk management but I always thought it was a way of stealing shares

I use margin with TD no change in my requirement today

I bought a biotech right after I bought amrn in 09' its at 75 now .. I bought them both in the 3's.. yes it can happen

I get that..I was referring to previous dilutions that hurt us..we lost a fortune

the obstacle we have and I've been long since 09' is the amount of shares outstanding .. i'm guessing we are going to be looking at some dilution after top line data is announced .. RRR of 15% makes this a big time drug with 100's of millions ROW benefitting from Vascepa .. I guess upon good top line read out we hook up immediately with big pharma in a co promotion we need their sales reps and those doc relationships for a quick ramp .. labeling shouldn't be a problem as FDA wants the adcom fiasco to go away without a bunch of publicity. if reduce it is successful; people died unnecessarily because of it; remember placebo like safety profile. market cap could easily early on be 10 bil which puts this at 30 bucks at current float...and going much further north as product development evolves of course we shall see- I added today and will do so tomorrow